This is a working overview of GLP-1 receptor, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-01-19 and is reviewed periodically as new material appears.
Retatrutide is an investigational synthetic peptide designed to activate three distinct receptor systems within a single molecule. Its pharmacological profile combines activity at the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor. This arrangement places it within a broader class of agents often described as multi-agonists, which contrast with compounds that engage one or two targets. Research interest centers on whether simultaneous signaling produces effects that single-receptor agonists cannot achieve alone. A single molecular entity also simplifies manufacturing and delivery logistics compared with combining separate agents.
Mechanistic proposals link each receptor to a different physiological role. Activation of the glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors is associated with reduced appetite, slower gastric emptying, and glucose-dependent insulin release. Glucagon receptor signaling, by contrast, is associated with increased energy expenditure and altered lipid handling, though it can also raise blood glucose. The design intent is to balance these contributions so that weight reduction is enhanced without unacceptable glycemic trade-offs. How well that balance holds across individuals is not fully resolved.
Retatrutide is an investigational synthetic peptide that acts on three receptor targets at once: glucose-dependent insulinotropic polypeptide, glucagon-like peptide-1, and glucagon. It is developed by Eli Lilly and appears in the literature and in trial registries under the code LY3437943. The molecule belongs to a class of engineered peptides designed to resist rapid breakdown and permit infrequent subcutaneous administration. No regulatory agency has approved it for clinical use, and all available human data come from controlled trials rather than from routine practice.
The intended pharmacology combines three signals in one molecule. GLP-1 receptor activation reduces appetite and slows gastric emptying, effects already exploited by approved incretin-based therapies. GIP receptor engagement is associated with improved insulin sensitivity and with direct effects on adipose tissue, although how much it contributes to overall outcomes is still debated. Glucagon receptor agonism raises energy expenditure and supports hepatic lipid handling, a mechanism that also tends to increase glucose output. The triple profile is hypothesized to produce a larger metabolic effect than single or dual agonism, but the relative weight of each receptor in humans is not settled.
Human evidence remains limited to controlled studies. A phase 2 trial in adults with obesity reported large, dose-dependent reductions in body weight over 48 weeks, with gastrointestinal events as the most frequently recorded adverse effect. Phase 3 programs designated TRIUMPH, for obesity, and TRANSCEND, for type 2 diabetes, are intended to confirm efficacy and to characterize safety in larger populations. Related studies are examining conditions such as knee osteoarthritis in people with obesity and metabolic liver disease. Open questions include long-term tolerability, effects on lean mass, and what happens after treatment is stopped.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Studied for metabolic indications |
| Receptor activity | GIP, GLP-1, and glucagon | Single molecule, three targets |
| Development status | Investigational | Not an approved therapy |
| Common synonym | LY3437943 | Development designation |
| Administration route | Subcutaneous injection | As used in clinical studies |
瑞他鲁肽是一种在研合成肽，同时作用于胰高血糖素样肽-1、葡萄糖依赖性促胰岛素多肽和胰高血糖素受体。该分子属于多受体激动剂类别，尚未获得任何监管机构的上市批准。当前临床开发主要针对肥胖和2型糖尿病，研究代号为LY3437943。已确立的信息包括受体靶点和部分中期试验结果；最终疗效、长期安全性和适用人群仍属开放问题。
开发进程从早期单次和多次给药研究推进至大规模后期试验。公开报告显示，参与者在体重和相关代谢指标上出现变化，但完整数据需经同行评审并接受独立复核。试验设计通常包括随机、双盲和对照设置，以区分药物效应与行为干预。监管提交和标签范围尚未确定；长期维持效果与心血管结局仍是开放问题。
Acting as a triple agonist, the molecule binds the GLP-1, GIP, and glucagon receptors. GLP-1 activity slows gastric emptying and dampens appetite, while GIP signaling contributes to insulin sensitivity and fat metabolism. Glucagon receptor engagement raises energy expenditure and encourages fat breakdown, although it can also elevate blood glucose. Combining three pathways is intended to yield larger weight reduction than single or dual agonists, and researchers continue to examine how the balance among them shapes tolerability.
Clinical studies have reported notable reductions in body weight among participants. Early trials measured safety and explored several dose levels, and later studies tracked body-weight change over months of treatment. Investigators also monitor effects on glycemic markers, liver fat, and blood lipids. Because the compound is still in development, questions about long-term safety, cardiovascular outcomes, and durability after treatment ends remain open.
Retatrutide is an investigational synthetic peptide engineered to activate three distinct hormone receptors within a single molecule. It targets the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor simultaneously. This triagonist design distinguishes it from earlier incretin-based compounds that act on one or two of these pathways. Structural modifications relative to native gut hormones extend its residence time in circulation. The molecule remains under clinical evaluation and is not approved for any indication.
Receptor activation produces downstream effects that differ by tissue. GLP-1 receptor signaling influences appetite regulation and insulin secretion in a glucose-dependent manner. GIP receptor activity contributes to metabolic handling of nutrients and may modulate adipose tissue. Glucagon receptor engagement raises energy expenditure and promotes hepatic lipid turnover, though the balance among these actions in humans is still being characterized. Preclinical models showed reductions in body weight and improved glycemic markers.
Clinical development has progressed through phase 2 trials in adults with obesity and type 2 diabetes, with phase 3 programs reported as ongoing. Reported outcomes include reductions in body weight and improvements in glycemic measures over defined treatment periods. Whether these effects translate into durable benefits after treatment ends remains an open question. Long-term safety data across broad populations are not yet complete, and regulatory decisions have not been announced.
多肽类化合物的表征通常依赖色谱与质谱联用技术。反相高效液相色谱用于评估纯度与有关物质，质谱用于确认分子量，肽图分析通过酶解碎片比对验证一级结构。这些手段组合使用，可以把目标产物与降解产物或类似物区分开来。单一方法往往不足以完成完整确认。
稳定性研究一般关注脱酰胺、氧化与聚集三类降解路径。脱酰胺多发生在天冬酰胺残基上，氧化常涉及甲硫氨酸与色氨酸，聚集则与浓度、温度以及容器界面接触有关。强制降解实验用于识别分子中较敏感的位点。这些结果会直接影响储存条件的设定与有效期的判断。
冻干粉通常在低温环境下保存，复溶之后需要按指定条件在较短时间内使用。反复冻融和剧烈振荡可能促进聚集，低吸附容器则能减少多肽在管壁上的损失。批号、日期与处理条件的完整记录，是后续复核与问题追溯的基础。
Liquids tend to have better thermal conductivity than gases, and the ability to flow makes a liquid suitable for removing excess heat from mechanical components. The heat can be removed by channeling the liquid through a heat exchanger, such as a radiator, or the heat can be removed with the liquid during evaporation. Water or glycol coolants are used to keep engines from overheating. The coolants used in nuclear reactors include water or liquid metals, such as sodium or bismuth. Liquid propellant films are used to cool the thrust chambers of rockets. In machining, water and oils are used to remove the excess heat generated, which can quickly ruin both the work piece and the tooling. During perspiration, sweat removes heat from the human body by evaporating. In the heating, ventilation, and air-conditioning industry (HVAC), liquids such as water are used to transfer heat from one area to another.
The United States accused Maduro of electoral fraud and presiding over a "narco-state". In March 2020, during Trump's first term, the United States Justice Department indicted Maduro on cocaine-trafficking conspiracy charges, which Maduro denied. Trump designated two Venezuelan drug gangs, the Tren de Aragua and the Cartel of the Suns, as Foreign Terrorist Organizations (FTOs) in January and July 2025 respectively, and alleged that the latter was led by Maduro. Maduro denied being involved in cartel leadership and characterized the designations as an attempt to use the war on drugs for regime change. Some Latin American crime experts have described the Cartel of the Suns as more of a general network of Venezuelan government and military corruption than as an organized group. Also in July 2025, a secret order instructed the US military to use force against cartels listed as terrorist organizations. In August 2025, the reward for Maduro's arrest increased to $50 million with US attorney general Pam Bondi calling Maduro "one of the largest narco-traffickers in the world and a threat to our national security." However, the Associated Press reported in January 2026 that while the US government has never publicly accused Delcy Rodríguez of criminal wrongdoing related to the drug trade, the Drug Enforcement Administration has nonetheless gathered an extensive intelligence file on Rodríguez since 2018 and designated her as a "priority target" in 2022—which the agency does for individuals suspected of having "significant impact" on the drug trade.
== Applications == Mass cytometry has research applications in medical fields including immunology, hematology, and oncology. It has been used in studies of hematopoiesis, cell cycle, cytokine expression, and differential signaling responses. MC has been used in various research fields, such as cancer biology, immunology, and neuroscience, to provide a more comprehensive understanding of tissue architecture and cellular interactions.
Sources: en.wikipedia.org
=== Populations === Lp(a) concentrations can vary by more than one thousand between individuals, from <0.2 to >200 mg/dL. Scientists have found that this range of concentrations has been observed in all populations studied. The mean and median concentrations differ among world populations. Most prominently, there is a two to threefold higher mean Lp(a) plasma concentration in populations of African descent compared to Asian, Oceanic, or European populations. The general inverse correlation between apo(a) isoform size and Lp(a) plasma concentration is observed in all populations. However, it was also discovered that mean Lp(a) associated with certain apo(a) isoforms varies between populations. In addition to size effects, mutations in the LPA promoter may lead to a decreased apo(a) production. The Atherosclerosis Risk in Communities (ARIC) Study is a community-based cohort from 4 geographically diverse US communities. The ARIC Study found that the proportion of Atherosclerotic Cardiovascular Disease cases potentially attributable to elevated Lp(a) was 10.2% among Black adults compared with 4.7% among white adults. The population-attributable fraction ratio for Black adults compared with white adults was 2.30. Because the hazard ratios for ASCVD associated with higher Lp(a) did not significantly differ between races, the ARIC study concluded that these differences appeared to be driven largely by racial differences in the distribution of Lp(a) levels.
Matrix-assisted laser desorption ionization can be used as a mass spectrometry imaging technique for relatively large molecules. It has recently been shown that the most effective type of matrix to use is an ionic matrix for MALDI imaging of tissue. In this version of the technique the sample, typically a thin tissue section, is moved in two dimensions while the mass spectrum is recorded. Although MALDI has the benefit of being able to record the spatial distribution of larger molecules, it comes at the cost of lower resolution than the SIMS technique. The limit for the lateral resolution for most of the modern instruments using MALDI is 20
==== Isomers ==== Alternative skeletal isomers of DOBU can also be produced, where the 4-(n-butyl) group of DOBU is replaced with any of the three other butyl isomers, the iso-butyl, sec-butyl and tert-butyl compounds being called DOIB, DOSB, and DOTB, respectively. All are significantly less potent than DOBU, with DOIB being active at around 10–15 mg, and DOSB at 25–30 mg. The most highly branched isomer DOTB was completely inactive in both animal and human trials. However, it was also reported that DOTB and DOAM partially generalized to DOM in animal drug discrimination tests.
Sources: en.wikipedia.org
This is because "anabolic" refers to muscle-building effects, while "androgenic" refers to induction and maintenance of male secondary sexual characteristics, but the latter in principle would include anabolic or muscle-building effects. Handelsman has argued that these terms should be discarded, and that instead, AAS should all simply be referred to as "androgens". Relatedly, Handelsman exclusively uses the term "androgen" to refer to these agents in his publications. Although the term "anabolic–androgenic steroid" is technically valid in describing two types of actions of these agents, Handelsman considers the term to be unnecessary and redundant. He likens it to hypothetical terms like "luteal–gestational progestins" or "mammary–uterine estrogens". Handelsman also notes that the term "anabolic steroid" is easily and unnecessarily confusable with corticosteroids. Besides AAS, Handelsman has criticized the term "selective androgen receptor modulator (SARM)" and claims about these agents as well.
==== Decomposition of mass ==== In order to quickly generate a manageable number of molecular formula candidates, the monoisotopic mass is decomposed into all possible molecular formulas that would lead to this mass. There are two definitions of the monoisotopic mass: (1) the sum of the masses of the most abundant naturally occurring stable isotope of each atom (i.e. the highest peak of the isotope pattern) (2) the sum of the masses of the lightest naturally occurring stable isotope of each atom (i.e. the peak of the isotope pattern with the lowest mass). For small molecules, the lightest peak is also mostly the highest peak of the isotope pattern. However, in the computational context of SIRIUS, the second definition is used. Decomposing the monoisotopic mass into all possible molecular formulas requires a mass interval taking into account the measurement inaccuracy of the instrument. This real-valued decomposition is transformed into a problem instance with integer masses by using a blowup factor. The resulting problem is known as Change-making problem which is well-studied and can be solved in runtime linear in the size of the output.
As the classification is most often used today, the oldest American think tank is the Carnegie Endowment for International Peace, founded in 1910. The Institute for Government Research, which later merged with two organizations to form the Brookings Institution, was formed in 1916. Other early twentieth century organizations now classified as think tanks include the Hoover Institution (1919), The Twentieth Century Fund (1919, and now known as the Century Foundation), the National Bureau of Economic Research (1920), the Council on Foreign Relations (1921), and the Social Science Research Council (1923). The Great Depression and its aftermath spawned several economic policy organizations, such as the National Planning Association (1934), the Tax Foundation (1937), and the Committee for Economic Development (1943). In collaboration with the Douglas Aircraft Company, the Air Force set up the RAND Corporation in 1946 to develop weapons technology and strategic defense analysis. The Hudson Institute is a conservative American think tank founded in 1961 by futurist, military strategist, and systems theorist Herman Kahn and his colleagues at the RAND Corporation. Recent members include Mike Pompeo, the former secretary of state under Donald Trump who joined in 2021. More recently, progressive and liberal think tanks have been established, most notably the Center for American Progress and the Center for Research on Educational Access and Leadership (CREAL). The organization has close ties to former United States President Barack Obama and other prominent Democrats.
Manufacturing sites were opened in 2011 in the Czech Republic for the industrial, pharmaceutical, chemical, and scientific markets while manufacturing sites for the semiconductor market were opened in South Korea. Most of Edwards' UK manufacturing capacity was moved, with abatement systems remaining in Clevedon, completing plans proposed under BOC in 2005. Edwards was awarded its seventh Queen's Award in 2012, and acquired USA-based Gamma Vacuum in 2013, maintaining the brand until this day. Gamma Vacuum specialises in ion and titanium sublimation pumps, with customers mainly in the scientific industry.
Sources: en.wikipedia.org
It is described as a single molecule that acts at three receptors: the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor. This triple activity distinguishes it from agents that target one or two of these pathways.
It is characterized in the literature as an investigational agent under clinical study. Approval status depends on jurisdiction, and readers should check current regulatory information rather than assume availability.
The combination is intended to pair appetite-related and glucose-related effects with mechanisms that increase energy expenditure. Whether the combined profile offers advantages over simpler agonists is the subject of ongoing research.
It is an investigational peptide that activates three hormone receptors: GIP, GLP-1 and glucagon. It is being studied mainly for obesity and type 2 diabetes, and it is not approved for any clinical use. Published information comes from controlled trials rather than from general practice.